Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 2 · 25%Low 0 · 0%Moderate 4 · 50%High 0 · 0%

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.93 [0.77, 1.13]
3 studies · 946 participants
Moderate

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.95 [0.87, 1.03]
5 studies · 1281 participants
Moderate

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 1.05 [0.07, 16.58]
1 study · 311 participants
Very low

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.08 [0.01, 1.42]
1 study · 311 participants
Very low

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 2.93 [1.86, 4.62]
5 studies · 1281 participants
Moderate

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 3.14 [1.85, 5.32]
4 studies · 863 participants
Moderate

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found